Tularaemia - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tularaemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Tularaemia - Pipeline Review, H1 2016', provides an overview of the Tularaemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Tularaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tularaemia
- The report reviews pipeline therapeutics for Tularaemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Tularaemia therapeutics and enlists all their major and minor projects
- The report assesses Tularaemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Tularaemia


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Tularaemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tularaemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tularaemia Overview 7
Therapeutics Development 8
Pipeline Products for Tularaemia - Overview 8
Pipeline Products for Tularaemia - Comparative Analysis 9
Tularaemia - Therapeutics under Development by Companies 10
Tularaemia - Therapeutics under Investigation by Universities/Institutes 11
Tularaemia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Tularaemia - Products under Development by Companies 14
Tularaemia - Products under Investigation by Universities/Institutes 15
Tularaemia - Companies Involved in Therapeutics Development 16
Aradigm Corporation 16
Arno Therapeutics, Inc. 17
DynPort Vaccine Company LLC 18
Emergent BioSolutions Inc. 19
EpiVax, Inc. 20
Grifols, S.A. 21
Merck & Co., Inc. 22
Tetraphase Pharmaceuticals Inc. 23
Tularaemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AR-12 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ARD-3100 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ARD-3150 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ciprofloxacin hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EV-035 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
solithromycin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SRI-011225 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TP-271 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
tularaemia [strain A] vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
tularaemia [strain B] vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
tularaemia vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
tularemia vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Tularaemia - Recent Pipeline Updates 55
Tularaemia - Dormant Projects 74
Tularaemia - Discontinued Products 75
Tularaemia - Product Development Milestones 76
Featured News & Press Releases 76
Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 76
May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 77
Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80

List of Tables

Number of Products under Development for Tularaemia, H1 2016 8
Number of Products under Development for Tularaemia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Tularaemia - Pipeline by Aradigm Corporation, H1 2016 16
Tularaemia - Pipeline by Arno Therapeutics, Inc., H1 2016 17
Tularaemia - Pipeline by DynPort Vaccine Company LLC, H1 2016 18
Tularaemia - Pipeline by Emergent BioSolutions Inc., H1 2016 19
Tularaemia - Pipeline by EpiVax, Inc., H1 2016 20
Tularaemia - Pipeline by Grifols, S.A., H1 2016 21
Tularaemia - Pipeline by Merck & Co., Inc., H1 2016 22
Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Tularaemia Therapeutics - Recent Pipeline Updates, H1 2016 55
Tularaemia - Dormant Projects, H1 2016 74
Tularaemia - Discontinued Products, H1 2016 75